Wednesday, June 10, 2026
🇺🇸 FDA

pharma · RSV Infection · NASH - Nonalcoholic Steatohepatitis · ENTA

ENANTA PHARMACEUTICALS

ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS clinical programs — 34 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
4 Kingsbury Ave, Watertown, Massachusetts 02472, US HQ
1995 Founded
145 Employees
Public company Type
ENTA · NYSE Ticker
Company details
Status
Public
HQ
4 Kingsbury Ave, Watertown, Massachusetts 02472, US
Founded
1995
Employees
145
Programs
34
Drugs
15
Patents
218
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

ENANTA PHARMACEUTICALS projects

34 ClinicalTrials.gov programs sponsored by ENANTA PHARMACEUTICALS.

ENANTA PHARMACEUTICALS has 34 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

34 programs

Clinical programs

  1. EDP-235

    ENANTA PHARMACEUTICALS INC

    COVID-19

    phase 2 small molecule completed

    3 trials

  2. EDP-305 1 mg

    ENANTA PHARMACEUTICALS INC

    Primary Biliary Cholangitis

    phase 2 small molecule completed

    1 trial

  3. EDP-305 1.5 mg

    ENANTA PHARMACEUTICALS INC

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule terminated

    1 trial

  4. EDP-305 Dose 1

    ENANTA PHARMACEUTICALS INC

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  5. EDP-323 Dose Regimen 1

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 2 small molecule completed

    1 trial

  6. EDP-420 / Duration of Treatment - 3 days

    ENANTA PHARMACEUTICALS INC

    Community Acquired Pneumonia

    phase 2 small molecule active

    1 trial

  7. EDP-938

    ENANTA PHARMACEUTICALS INC

    Respiratory Syncytial Virus

    phase 2 small molecule completed

    1 trial

  8. EDP-938

    ENANTA PHARMACEUTICALS INC

    Respiratory Syncytial Virus (RSV)

    phase 2 small molecule completed

    2 trials

  9. EDP-938

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 2 small molecule completed

    6 trials

  10. EDP-938

    ENANTA PHARMACEUTICALS INC

    Respiratory Syncytial Virus Infections

    phase 2 small molecule terminated

    1 trial

  11. EDP-938 Dose 1

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 2 small molecule completed

    1 trial

  12. EDP-938, EDP-938 Placebo tablets

    ENANTA PHARMACEUTICALS INC

    Respiratory syncytial virus (RSV)

    phase 2 small molecule active

    1 trial

  13. zelicapavir

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 2 small molecule active

    1 trial

  14. DEB025

    ENANTA PHARMACEUTICALS INC

    Hepatitis C Virus

    phase 1 small molecule completed

    1 trial

  15. EDP 305

    ENANTA PHARMACEUTICALS INC

    Presumptive NAFLD

    phase 1 small molecule completed

    1 trial

  16. EDP 305

    ENANTA PHARMACEUTICALS INC

    NASH

    phase 1 small molecule completed

    1 trial

  17. EDP-235

    ENANTA PHARMACEUTICALS INC

    SARS CoV 2 Infection

    phase 1 small molecule completed

    1 trial

  18. EDP-297

    ENANTA PHARMACEUTICALS INC

    NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis

    phase 1 small molecule completed

    1 trial

  19. EDP-305

    ENANTA PHARMACEUTICALS INC

    NASH - Nonalcoholic Steatohepatitis

    phase 1 small molecule completed

    2 trials

  20. EDP-322

    ENANTA PHARMACEUTICALS INC

    Skin and Soft Tissue Infections

    phase 1 small molecule completed

    1 trial

  21. EDP-322

    ENANTA PHARMACEUTICALS INC

    MRSA, SSTI

    phase 1 small molecule completed

    1 trial

  22. EDP-323

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 1 small molecule completed

    3 trials

  23. EDP-494

    ENANTA PHARMACEUTICALS INC

    Hepatitis C

    phase 1 small molecule completed

    1 trial

  24. EDP-514

    ENANTA PHARMACEUTICALS INC

    Hepatitis B

    phase 1 small molecule completed

    1 trial

  25. EDP-514

    ENANTA PHARMACEUTICALS INC

    Chronic HBV Infection

    phase 1 small molecule completed

    2 trials

  26. EDP-721

    ENANTA PHARMACEUTICALS INC

    Chronic Hepatitis B Virus Infection

    phase 1 small molecule terminated

    1 trial

  27. EDP-788

    ENANTA PHARMACEUTICALS INC

    Safety in Normal Volunteers

    phase 1 small molecule completed

    1 trial

  28. EDP-788

    ENANTA PHARMACEUTICALS INC

    Healthy

    phase 1 small molecule terminated

    1 trial

  29. EDP-978

    ENANTA PHARMACEUTICALS INC

    Chronic Inducible Urticaria

    phase 1 small molecule active

    1 trial

  30. EDP239

    ENANTA PHARMACEUTICALS INC

    Hepatitis C

    phase 1 small molecule completed

    1 trial

  31. Fluconazole

    ENANTA PHARMACEUTICALS INC

    NASH - Nonalcoholic Steatohepatitis

    phase 1 small molecule completed

    1 trial

  32. Midazolam

    ENANTA PHARMACEUTICALS INC

    NASH

    phase 1 small molecule completed

    1 trial

  33. intraconazole

    ENANTA PHARMACEUTICALS INC

    NASH - Nonalcoholic Steatohepatitis

    phase 1 small molecule completed

    1 trial

  34. zelicapavir (therapeutic dose)

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does ENANTA PHARMACEUTICALS have?

34 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.